文献速递中枢神经肿瘤放疗放疗物理与技术

FLAIR 纳入对胶质母细胞瘤失败模式与结局的影响:UNITED 前瞻性自适应放疗试验结果

Influence of FLAIR inclusion on patterns-of-failure and outcomes in glioblastoma: results from the UNITED prospective adaptive radiotherapy trial.
PubMed 文献 · Radiother Oncol · 2026-05-15

该研究基于前瞻性2期MR引导自适应放疗试验,评估胶质母细胞瘤临床靶区是否纳入FLAIR高信号区对失败模式和生存的影响。98例患者分为未纳入、存在但未纳入和纳入三组,复发以中心型为主且组间无差异,省略FLAIR高信号区未对失败模式或生存产生负面影响。

要点

  • 在5 mm小边缘MR引导自适应放疗中,省略FLAIR高信号区未影响失败模式。
  • 三组间复发部位、rGTV覆盖率和剂量均无显著差异。
  • 无进展生存和总生存组间比较均无统计学差异。

核心结论

  • 在小边缘MR引导自适应放疗范式下,省略FLAIR高信号区未对失败模式或生存结局产生负面影响。

研究设计与样本

  • 前瞻性2期试验的事后分析,纳入新诊断胶质母细胞瘤患者,接受MR-Linac每周在线自适应放化疗(NCT04726397)。
  • 共98例患者,按FLAIR高信号区处理方式分为三组:无FLAIR高信号区超出5 mm(NF)24例、存在但未纳入(FNI)27例、纳入(FI)47例。

主要发现

  • 69例复发以中心型为主(65-72%),组间无差异(p=0.717)。
  • 复发GTV在CTV内的中位覆盖率为97.9%,组间可比(p=0.105),估计复发GTV剂量亦组间可比。
  • NF、FNI、FI组的中位无进展生存分别为10.5、8.0、8.6个月(p=0.279),中位总生存分别为16.9、15.8、13.4个月(p=0.389)。
  • 多变量分析显示不同勾画策略对结局无显著差异。

关键数值与推荐

  • 大体肿瘤体积包括切除腔和残余强化肿瘤,临床靶区定义为大体肿瘤体积+5 mm,是否纳入超出5 mm的FLAIR高信号区由临床医生决定。

临床怎么用

  • 在采用5 mm小边缘的MR引导自适应放疗中,临床医生可考虑不将FLAIR高信号区纳入临床靶区而不影响失败模式或生存。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inclusion of the peritumoral FLAIR-hyperintense-region (FHR) within the clinical target volume (CTV) for glioblastoma (GBM) varies across guidelines. Using data from a prospective phase 2 trial employing small-margin MR-guided adaptive radiotherapy (RT), we evaluated whether inclusion of FHR influences the pattern-of-failure (POF) and clinical outcomes. METHODS: Patients with newly diagnosed GBM underwent chemoRT with weekly online-adaptive planning on an MR-Linac (NCT04726397). The gross tumor volume (GTV) included the resection cavity and residual enhancing tumor. The CTV was defined as GTV + 5 mm, with inclusion of FHR beyond 5 mm at the clinician's discretion. For this post hoc analysis, three contour categories were identified: no FHR beyond 5 mm (NF), FHR present but not included (FNI), and FHR included (FI). At radiographic progression, the recurrent GTV (rGTV) was delineated on co-registered MRIs to quantify overlap with the CTV and summed RT dose. rGTV coverage, dose/volume histogram metrics, progression-free survival (PFS), and overall survival (OS) were compared among groups. RESULTS: Among 98 patients, 24 were NF, 27 FNI, and 47 FI. Recurrences (n = 69) were predominantly central (65-72%) with no difference between groups (p = 0.717). Median rGTV coverage within the CTV was 97.9% and was comparable across strategies (p = 0.105), as was estimated rGTV dose. Median PFS and OS for the NF, FNI, and FI cohorts were 10.5, 8.0, and 8.6 months (p = 0.279) and 16.9, 15.8, and 13.4 months (p = 0.389), respectively. Multivariable analysis revealed no significant differences between contouring strategies on outcomes. CONCLUSION: Within a small-margin MR-guided adaptive RT paradigm, omission of FHR did not negatively influence the POF or survival outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ghosh S, Stewart J, Ruschin M, et al. Influence of FLAIR inclusion on patterns-of-failure and outcomes in glioblastoma: results from the UNITED prospective adaptive radiotherapy trial. Radiother Oncol. 2026. PMID: 42142536. doi:10.1016/j.radonc.2026.111579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。